Free Guide to Tuberculosis Testing Options

Understanding Tuberculosis and Why Testing Matters

Tuberculosis (TB) is an infectious disease caused by bacteria called Mycobacterium tuberculosis. According to the World Health Organization, approximately 10 million people develop TB each year worldwide, and about 1.3 million people die from the disease. In the United States, the CDC reported 7,503 TB cases in 2022, which represents a rate of about 2.2 cases per 100,000 people. While these numbers may seem low compared to other countries, TB remains a serious public health concern that requires prompt detection and treatment.

TB spreads through the air when an infected person coughs, sneezes, or speaks. Not everyone exposed to TB bacteria becomes sick. When a person breathes in TB bacteria, the infection can develop in two ways. Latent TB infection occurs when the bacteria live in the body but don't cause illness, and the person cannot spread the disease to others. Active TB disease develops when the bacteria multiply and cause symptoms, and the person can transmit the disease to others. Understanding the difference between these two conditions is crucial because they require different testing approaches and treatment plans.

Testing for TB serves several important purposes. First, it identifies whether someone has been exposed to TB bacteria. Second, it determines whether a person has latent or active TB infection. Third, early detection through testing allows doctors to start treatment before the disease causes serious damage to the lungs and other organs. People with untreated active TB can infect others for months, making testing an important public health measure.

Certain groups face higher risks of TB infection and may benefit from understanding available testing options. These groups include people who have lived in close contact with someone who has active TB, healthcare workers, people with weakened immune systems, those living in congregate settings like shelters or prisons, and people who have recently immigrated from countries where TB is more common. However, anyone can develop TB, which is why information about testing options is valuable for the general public.

Practical Takeaway: TB is a serious but treatable disease. Understanding that TB exists in two forms—latent and active—helps explain why different testing methods exist. Learning about testing options allows people to take action if they think they may have been exposed to TB or are experiencing symptoms.

The Tuberculin Skin Test (TST): How It Works and What to Expect

The tuberculin skin test (TST), also known as the Mantoux test or purified protein derivative (PPD) test, is one of the oldest and most widely used TB testing methods. The test involves injecting a small amount of tuberculin purified protein derivative into the skin, usually on the forearm. A nurse or healthcare provider will clean a small area of skin and use a thin needle to inject the substance just under the top layer of skin. The injection creates a small bump or bleb at the injection site, which is completely normal and expected.

After receiving a TST, a person must return to the healthcare provider 48 to 72 hours later to have the injection site examined. The provider will measure the size of any hardening or swelling (called induration) that has developed at the injection site. Importantly, redness alone does not indicate a positive test—only the size of the hardened area matters. The measurement is recorded in millimeters. A healthcare provider interprets the results by comparing the measurement against established guidelines that take into account the person's individual risk factors for TB. Different measurements mean different things depending on a person's specific circumstances.

The TST has several advantages that make it a popular choice for TB screening. The test is inexpensive, costing between $5 and $15 in most settings. It requires no special equipment beyond basic injection supplies. The test can be performed in various healthcare settings, including doctor's offices, clinics, and public health departments. It works well for screening large groups of people, which is why it remains common in schools, workplaces, and healthcare facilities. The TST has been used for many decades and has extensive data supporting its reliability.

However, the TST also has limitations. The test cannot distinguish between latent TB infection and active TB disease—additional tests are needed to make that determination. False positive results can occur in people who previously received the BCG vaccine (used in many countries outside the United States) or who have been infected with certain non-TB bacteria. False negative results can occur in people with weakened immune systems, including those with HIV/AIDS, or in people tested too soon after infection (before the immune system develops a response). Additionally, the two-step process requiring a return visit may be inconvenient for some people.

Practical Takeaway: The TST is a low-cost, accessible first-line screening test that requires two visits to a healthcare provider. Understanding that measurement size matters more than redness helps people know what to expect during the results appointment. However, a positive TST requires additional testing to determine if someone has active TB disease or latent infection.

Interferon-Gamma Release Assays (IGRAs): Blood-Based Testing Options

Interferon-gamma release assays (IGRAs) represent a newer approach to TB testing that uses a blood sample instead of a skin injection. There are three FDA-approved IGRAs available in the United States: the QuantiFERON-TB Gold In-Tube (QFT-GIT), the QuantiFERON-TB Gold Plus (QFT-Plus), and the T-SPOT.TB test. These tests measure the immune system's response to TB antigens by analyzing white blood cells in a blood sample. When blood from a person with TB infection is exposed to TB antigens in the laboratory, the immune cells release interferon-gamma, which the test measures.

The IGRA testing process is straightforward from a patient's perspective. A healthcare provider draws blood into special tubes containing TB antigens, and the blood sample is then sent to a laboratory for analysis. Results are typically available within 24 hours, though some laboratories may take longer. Unlike the TST, IGRAs require only one visit to the healthcare provider. There is no need for a follow-up appointment to have results measured, which can be more convenient for people with busy schedules or limited transportation options.

IGRAs offer several advantages over the TST. They are not affected by prior BCG vaccination, which eliminates one source of false positive results. IGRAs are less affected by non-TB mycobacteria, so they provide more specific results in certain populations. The test requires only one clinic visit, reducing barriers related to follow-up appointments. IGRAs may be more sensitive in certain populations, including children under five years old and people with HIV infection. Additionally, some people find a blood draw more acceptable than a skin injection.

IGRAs also have limitations that may affect their use in certain situations. The tests are more expensive than TST, typically costing $100 to $200 or more per test. Specialized laboratory equipment is required to perform IGRAs, so they are not available in all healthcare settings. False negative results can occur in people with weakened immune systems, similar to TST limitations. Some research suggests IGRAs may be less sensitive in children under two years old. Additionally, like the TST, a positive IGRA does not distinguish between latent and active TB infection—additional testing is necessary to make that determination.

Practical Takeaway: IGRAs are blood-based tests that offer advantages such as single-visit testing and lack of BCG vaccine interference. They cost more than TST but may be more convenient and accurate for certain populations. Learning about both TST and IGRA options helps people understand what tests they might encounter in different healthcare settings.

Testing for Active Tuberculosis Disease: Chest X-Rays and Sputum Tests

When someone has symptoms suggesting active TB disease or has tested positive on a TST or IGRA, additional tests are necessary to confirm whether active disease is present. Active TB most commonly affects the lungs, so chest X-rays play a central role in diagnosis. A chest X-ray can reveal characteristic patterns in the lungs that suggest TB, particularly in the upper portions of the lungs where TB bacteria prefer to grow. The X-ray shows areas of infiltration, cavitation (holes in the lung tissue), or other abnormalities that differ from a normal, healthy lung. However, a chest X-ray alone cannot definitively diagnose TB—it only raises suspicion and leads to further testing.

Sputum smear microscopy and sputum culture are the gold standard tests for confirming active TB disease. Sputum is mucus that people cough up from their lungs. When